Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Dermorphin7 residuesYAFGYPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, Dermorphine
Thirty to forty times more potent than morphine, and it comes from a frog. Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a seven-amino-acid opioid peptide first isolated in 1981 from the skin of South American tree frogs in the genus Phyllomedusa. A single 1985 human trial showed intrathecal dermorphin outperforming morphine for postoperative pain. No further human trials followed. Research interest has remained mostly academic since then. Dermorphin's primary notoriety comes from horse racing doping scandals across Oklahoma and Louisiana between 2011 and 2013. This is a controlled substance analog with lethal overdose potential. It appears here strictly for research reference.
Seven amino acids from a tree frog's skin changed opioid pharmacology in 1981. Dermorphin (CAS 77614-16-5; H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) binds mu-opioid receptors with a Ki of 0.2-0.5 nM. That makes it one of the most potent naturally occurring analgesics ever identified. Erspamer and colleagues first characterized it from Phyllomedusa sauvagei skin secretions [1]. The mechanism is straightforward. A rare D-alanine at position 2 locks the peptide backbone into an ideal shape for mu-receptor activation and blocks enzymatic breakdown. Kreil confirmed in 1987 that frog skin cells convert L-alanine to D-alanine through post-translational isomerization [2]. When administered intrathecally to rodents, dermorphin proved 3,000 to 5,000 times more active than spinal morphine in standard pain assays [3]. In 1985, a small randomized controlled trial tested intrathecal dermorphin against morphine and placebo in postoperative patients. Dermorphin won. Development stopped there. No pharmaceutical company ever advanced it into Phase 2. The field moved toward synthetic opioids instead. Dermorphin resurfaced in 2011, but not in a lab. Horse trainers in Oklahoma and Louisiana had been injecting it into racehorses because standard equine drug screens couldn't detect it. Approximately 30 positive cases were identified after LC-MS/MS testing methods were developed [4]. Nine Louisiana trainers were sanctioned. The ARCI now classifies it as Class I prohibited. A 2018 review by Cascio and colleagues [5] explored dermorphin's theoretical role in palliative oncological pain, noting its slower tolerance development compared to morphine. That remains entirely theoretical. No modern clinical program exists. Under the US Federal Analogue Act (21 U.S.C. 813), dermorphin is almost certainly treated as a Schedule I analog when intended for human consumption.
Dermorphin targets the mu-opioid receptor (MOR) with a binding affinity of approximately 0.46 nM, confirmed by equilibrium binding studies using tritiated dermorphin in rat brain membranes [6]. Selectivity for mu over delta and kappa subtypes exceeds 1,000-fold. Once bound, dermorphin triggers Gi/Go protein coupling. Three downstream effects follow. Adenylyl cyclase gets inhibited, dropping intracellular cAMP. Voltage-gated N-type calcium channels close, cutting neurotransmitter release. Inwardly rectifying potassium channels (GIRKs) open, hyperpolarizing the neuron. Pain signal transmission shuts down at both spinal and supraspinal levels. The peptide's structure explains its potency. The N-terminal tetrapeptide Tyr-D-Ala-Phe-Gly is the "message" domain, responsible for receptor activation. The C-terminal tripeptide Tyr-Pro-Ser-NH2 is the "address" domain, directing selectivity toward mu-receptors specifically. Something interesting happens after binding. Dermorphin promotes MOR internalization through beta-arrestin recruitment. When researchers blocked this internalization, the analgesic effect dropped [7]. Receptor trafficking isn't just a cleanup process; it actively contributes to pain relief. At the systems level, dermorphin modulates descending pain inhibitory pathways from the periaqueductal gray and rostral ventromedial medulla. It amplifies the body's own pain suppression circuits rather than working only at the site of injury.
Potent mu-opioid agonist with 30-40x the analgesic potency of morphine in preclinical models. One 1985 human RCT (intrathecal, postoperative pain) showed superiority over morphine and placebo. No further human trials conducted. No approved human use in any jurisdiction.
Erspamer et al. 1981 (PMID 7195758): pharmacological characterization. Single 1985 intrathecal human RCT (underpowered, single-site). Robinson et al. 2015 (PMID 25376170): equine PK. Cascio et al. 2018 (PMID 30203008): palliative care review.
Only one small human RCT (1985); never replicated. No Phase 2/3 trials. All human dosing is extrapolated from animal data. No published human PK/PD studies beyond the 1985 trial. Research abandoned after 1985 in favor of synthetic opioids.
No documented human self-use protocols in peptide or harm-reduction communities. Community awareness is almost entirely limited to equine doping context. Extreme caution consensus among the few discussions that exist.
Science-only: published research exists (preclinical + 1 human RCT from 1985) but no community human-use protocols have emerged. The compound occupies a niche as an academic/pharmacological research tool, not a self-use peptide.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Single dose |
| Moderate | 100mcg | Single dose |
| Aggressive | 200mcg | Single dose |
Dermorphin is not a self-use peptide. It's listed as a research reference because its pharmacology is genuinely interesting, but the risk profile makes it wholly inappropriate for self-administration. If you're handling this in a research context, the reconstitution math works like this. A 1 mg vial reconstituted with 1 mL bacteriostatic water gives a 1 mg/mL (1,000 mcg/mL) solution. On a U-100 insulin syringe, each unit equals 10 mcg. So 50 mcg is 5 units, 100 mcg is 10 units, 200 mcg is 20 units. The thing most people miss: plasma half-life (~1.3 min in rodents, ~5.4 min in horses) does not equal duration of action. Receptor binding and beta-arrestin-mediated internalization sustain the analgesic effect for 45-90 minutes IV, and up to 48 hours intrathecally. Don't confuse clearance from blood with clearance from the receptor. Naloxone on hand is non-negotiable. Analytical-grade sourcing with LC-MS/MS purity verification is also non-negotiable.
DEPENDENCE WARNING: Dermorphin should not be used in repeated dosing protocols outside of strictly controlled research settings. Even short-duration repeated exposure carries risk of physical dependence and opioid withdrawal. There is no established or recommended cycling protocol for human use. Any investigational protocol must include naloxone availability and medical supervision. Tolerance to analgesic effects can develop within days of repeated administration.
Repeated mu-opioid receptor activation leads to beta-arrestin-mediated receptor internalization, desensitization, and downregulation. Analgesic tolerance develops within days. Physical dependence compounds cycling risk: off-periods carry opioid withdrawal risk. The 1-on/4-off cycling structure in the peptides.ts entry is a harm-reduction framework, NOT a recommended use protocol. In practice, no cycling protocol is appropriate outside strictly controlled research.
Or use the universal Peptide Calculator for any peptide.
Expected: In preclinical models: rapid onset analgesia (peak within minutes IV), duration 45-90 min peripheral, up to 48 hours intrathecal. Human outcomes not established beyond single 1985 RCT.
Monitor: Continuous respiratory monitoring required. Pulse oximetry and naloxone reversal agent mandatory in any research setting. Opioid withdrawal assessment if any repeated dosing occurs.
Verify naloxone (0.4-2 mg IV/IM) is immediately accessible before opening the vial. Non-negotiable safety requirement.
Reconstitute 1 mg lyophilized dermorphin with 1 mL bacteriostatic water. Gently swirl until dissolved. Do not vortex. This yields a 1,000 mcg/mL solution.
Syringe unit conversion (U-100 insulin syringe): 50 mcg = 5 units. 100 mcg = 10 units. 200 mcg = 20 units.
For a 2 mg vial reconstituted with 2 mL bacteriostatic water, the same concentration applies: 1,000 mcg/mL. Unit conversions remain identical.
Use a 29-31 gauge insulin syringe for subcutaneous administration. Clean the injection site with an alcohol swab. Inject subcutaneously into the abdomen or thigh.
Continuous pulse oximetry and respiratory rate monitoring required for at least 60 minutes post-administration. SpO2 must stay at or above 95%. Respiratory rate must stay at or above 12 breaths per minute.
Store reconstituted solution at 2-8 degrees C and use within 7 days. For IV research applications, use within 24 hours. Lyophilized powder stores up to 24 months at -20 degrees C, desiccated, protected from light.
Follow institutional controlled substance handling protocols: locked storage, usage logs, and proper waste disposal.
FOR RESEARCH USE ONLY. No human therapeutic protocol exists.
Severe additive CNS and respiratory depression; combination is potentially fatal. Black box warning equivalent.
Do not combineAdditive mu-opioid receptor activation; compounded respiratory depression and overdose risk.
Do not combinePotentiates sedation and respiratory depression via CNS depression.
Do not combineRisk of serotonin syndrome and unpredictable potentiation of opioid effects. Contraindicated.
Do not combineRespiratory depression can kill you. That is the primary risk with dermorphin, and its 30-40x morphine potency makes the margin for error vanishingly small. Bolus injection induced apnea in animal models. In any setting where this peptide is handled, naloxone (0.4-2 mg IV) must be within arm's reach. The full spectrum of mu-opioid agonist effects applies. Profound sedation. Nausea and vomiting. Constipation and reduced gastrointestinal motility. Miosis. Bradycardia. Urinary retention. These are well-characterized opioid effects, but dermorphin's extreme potency compresses the dose-response curve. Small dosing errors produce disproportionate consequences. Human safety data is almost nonexistent. One 1985 intrathecal trial and no modern pharmacovigilance data. Everything known about dermorphin's side effect profile comes from preclinical animal models and equine pharmacokinetic studies. That's roughly 250 PubMed publications total, with no controlled human dose-finding work. Physical dependence develops with repeated administration. Preclinical data suggest withdrawal may be less intense than morphine withdrawal at equianalgesic doses, but "less intense opioid withdrawal" is still opioid withdrawal. Symptoms include agitation, muscle pain, insomnia, diarrhea, and autonomic instability. Dependence signs can emerge within days of repeated dosing. Addiction potential is high. Dermorphin is a potent mu-opioid agonist. Mu-receptor activation drives the reward pathway. Anyone with a history of substance use disorder faces extreme risk. Tolerance to the analgesic effect develops with chronic use, driving dose escalation. Drug interactions compound every risk listed above. Benzodiazepines combined with dermorphin create severe additive CNS and respiratory depression; that combination can be fatal. The same applies to other opioid agonists, alcohol, barbiturates, and general anesthetics. MAO inhibitors create risk of serotonin syndrome and unpredictable opioid potentiation. Gabapentinoids (gabapentin, pregabalin) carry an FDA warning for increased respiratory depression when combined with opioids. Contraindications are extensive. Pregnancy and breastfeeding (opioid peptides cross the placental barrier). Respiratory insufficiency or sleep apnea. Severe hepatic impairment. Concurrent MAO inhibitor use. Paralytic ileus. Traumatic brain injury with raised intracranial pressure. Unmonitored settings without naloxone access. Pediatric populations have zero safety data. Stop immediately and seek emergency care if respiratory rate drops below 12 breaths per minute, SpO2 falls below 95%, or any signs of opioid toxicity appear.
Verify Dermorphin dosing and safety with a second opinion
No regulatory oversight for research-grade dermorphin. Equine doping history creates illicit supply chains with unknown purity. Extreme potency (30-40x morphine) means even small contamination or dosing errors carry lethal risk. Federal Analogue Act legal exposure in US.
| Test | When | Target |
|---|---|---|
| Respiratory rate and SpO2 (pulse oximetry) | Continuous during and 60 min post-administration in any research setting | SpO2 ≥ 95%; RR ≥ 12 breaths/min |
| Opioid withdrawal assessment (COWS scale or equivalent) | Before and after any repeated-dosing research protocol | COWS score < 5 before next dose cycle |
| Liver function tests (ALT, AST, bilirubin) | Baseline and after any multi-day research protocol | — |
| Naloxone availability verification | Before every session | Naloxone 0.4-2 mg IV/IM on hand at all times |
Primary lethal risk is respiratory depression; mu-opioid agonism at this potency can cause apnea
Physical dependence can emerge within days of repeated administration
Hepatic peptidase metabolism; monitoring for metabolic burden in extended research contexts
Emergency reversal agent; must be immediately accessible: non-negotiable safety requirement
Rapid onset of analgesia in preclinical models. Peak plasma concentration reached almost immediately after IV administration. Profound mu-opioid receptor activation with measurable antinociceptive response in rodent hot-plate and tail-flick assays.
Sustained analgesic effect despite rapid plasma clearance (t1/2 ~1.3 min), suggesting tissue-level receptor binding persists beyond plasma availability. Respiratory rate depression observed in animal models.
Gradual waning of analgesic effect after single-dose administration. Duration of action is longer than plasma half-life due to slow receptor dissociation kinetics and receptor internalization dynamics.
Return to baseline nociceptive thresholds after single dose. Complete metabolic clearance from plasma via hepatic and renal peptidase activity.
Measurable analgesic tolerance develops with repeated administration in animal models, though onset is slower than with equivalent morphine protocols. Signs of physical dependence may emerge.
Minutes 0-5 (IV/SC): Pain relief hits fast in preclinical models. Peak analgesia arrives within 1-5 minutes after IV administration. Plasma concentration peaks almost immediately. Mu-opioid receptor activation is profound, measurable across standard rodent nociceptive assays (hot plate, tail flick). No human self-use data exists. Respiratory depression, sedation, miosis, and bradycardia have all been observed in animal models during this phase. Minutes 5-30: Plasma clears quickly (t1/2 roughly 1.3 min rodent, 5.4 min equine). The peptide is gone from blood fast. But tissue-level receptor binding sustains the analgesic effect well beyond plasma availability. Respiratory depression risk is highest in this window. Nausea and reduced GI motility also show up in animal models. Minutes 30-90: The analgesic effect gradually fades after a single dose. Duration outlasts the plasma half-life because of slow receptor dissociation and beta-arrestin-mediated receptor internalization. The receptor doesn't let go as fast as the blood clears the peptide. Hours 2-6: Baseline pain thresholds return. Hepatic and renal peptidases complete metabolic clearance. Terminal elimination half-life is approximately 45 minutes IV based on equine data from Robinson and colleagues [9]. Days 3-7 (repeated dosing): This is where dependence becomes the defining concern. Analgesic tolerance develops in animal models, though onset is slower than with equivalent morphine protocols. Physical dependence signs emerge with repeated dosing. Withdrawal on cessation includes agitation, muscle pain, insomnia, diarrhea, and autonomic instability. Even short repeated-dosing protocols require dependence monitoring and withdrawal management planning. No human protocol data exists.
Peak analgesia within 1-5 min IV (preclinical). Plasma Cmax reached almost immediately IV. Profound mu-opioid receptor activation measurable in rodent nociceptive assays (hot plate, tail flick).
No human self-use data available.
Plasma t1/2 ~1.3 min (rodent) / ~5.4 min (equine); tissue-level receptor binding sustains analgesia beyond plasma availability. Respiratory depression risk highest in this window.
No human data.
Gradual return to baseline nociception after single dose. Duration longer than plasma half-life due to slow receptor dissociation and beta-arrestin-mediated internalization dynamics.
No human data.
Return to baseline nociceptive thresholds. Hepatic and renal peptidase-mediated metabolic clearance complete. Terminal elimination t1/2 ~45 min IV (equine data).
No human data.
Measurable analgesic tolerance develops in animal models, though onset is slower than with equivalent morphine protocols. Physical dependence signs emerge with repeated dosing. Naloxone-precipitated withdrawal less intense than morphine at equianalgesic doses in preclinical models.
No human data. This timeline zone is where dependence risk becomes critical.
Source: Plasma t1/2 ~1.3 min; terminal elimination t1/2 ~45 min IV in horses (Robinson et al., 2015, PMID 25376170)
Loading the interactive decay curve.
Dermorphin is not explicitly listed in the US Controlled Substances Act schedules. It almost certainly falls under the Federal Analogue Act (21 U.S.C. 813), which treats substances structurally and pharmacologically similar to Schedule I or II drugs as Schedule I when intended for human consumption. Morphine is Schedule II. Dermorphin is a functional analog with 30-40x the potency. The Association of Racing Commissioners International (ARCI) classifies dermorphin as a Class I prohibited substance in equine competition, the most serious category. Federal charges were filed in at least one case related to the 2011-2013 horse racing doping scandal. The World Anti-Doping Agency (WADA) prohibits all opioid peptides in competition. Athletes should consider dermorphin banned at all times given its opioid mechanism. International regulations vary. Multiple jurisdictions classify dermorphin as a controlled or banned substance. Researchers should verify local regulations before procurement, possession, or use. This content is provided for educational and research reference only. Dermorphin is not approved for human therapeutic use in any jurisdiction worldwide. Nothing on this page constitutes medical advice or encouragement to obtain, possess, or self-administer this compound.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
